Afatinib versus other EGFR inhibitors

Afatinib is a second-generation EGFR inhibitor. As a targeted therapy drug, it plays an important role in the treatment of non-small cell lung cancer (NSCLC) . Compared with other EGFR inhibitors (such as gefitinib, erlotinib and other first-generation EGFR inhibitors), afatinib is different in terms of therapeutic effect, resistance mechanism and side effects.

The mechanism of action of afatinib is different from that of first-generation EGFR inhibitors. It not only inhibits EGFR exon 19 deletion and exon 21L858R mutation, but also inhibits other receptors such as HER2, HER4, etc., so it may be more effective against certain mutated types of lung cancer. In contrast, first-generation EGFR inhibitors primarily target mutations in EGFR but fail to adequately inhibit other receptors.

In terms of efficacy, afatinib showed more durable responses in some patients, especially in a patient population with diverse EGFR mutation types. Studies have shown that compared with gefitinib and erlotinib, afatinib exhibits stronger anti-tumor activity in certain subgroups of patients, especially in patients with EGFR-mutated lung cancer.

However, the side effects of afatinib are more obvious than those of the first generation EGFR inhibitors, especially rash and diarrhea. Because it inhibits a wide range of receptors, the side effects of afatinib may be more severe in some patients. Therefore, in clinical treatment, although afatinib may have advantages in efficacy, the management of its side effects is also very important. Patients should rationally adjust drug dosages and take effective auxiliary treatment measures under the guidance of doctors to ensure therapeutic effects and reduce the occurrence of side effects.

To sum up, afatinib may have stronger efficacy in treating some EGFR-mutated non-small cell lung cancer compared with first-generation EGFR inhibitors. However, its side effects are more significant. Therefore, in clinical application, it is necessary to decide whether to use this drug based on the specific situation of the patient.

Reference materials:https://www.giotrif.com/